MannKind Corporation (MNKD)

Over the past six months, MannKind Corp.'s stock price has risen by 30.58%, with a share price of $5.36 as of November 25, 2025, representing an 18.54% decline from November 26, 2024, and a 52-week range of $3.38 to $7.07. In Q1 2025, MannKind reported an 18% year-over-year increase in total revenues to $78 million, driven by Tyvaso DPI royalties and Afrezza demand, with a 24% increase in net income. Q2 2025 saw a 6% year-over-year increase in total revenues to $76.5 million, with Tyvaso DPI royalty revenues rising 22% and Afrezza net product sales growing 13%, though revenues from V-Go and collaboration revenues were down. In Q3 2025, the company reported record revenue of $82 million, a 17% increase year-over-year, with significant contributions from Tyvaso DPI and Afrezza, and a non-GAAP net income of $22.4 million. MannKind acquired scPharmaceuticals in October 2025, which is expected to enhance its portfolio with FUROSCIX. Truist Securities initiated coverage with a "Buy" rating and a $9.00 price target in November 2025, while other firms maintained positive ratings and adjusted price targets; Oppenheimer raised its price target from $12.00 to $15.00 in September 2025. Recently, insiders, including EVP Sanjay R. Singh and Stuart A. Tross, have sold shares.

The provided information does not explicitly detail demand seasonality for MannKind Corporation's products and services, but recent earnings reports indicate increased demand for Afrezza and Tyvaso DPI, while V-Go has experienced decreased demand, suggesting that demand can fluctuate based on various factors without a clear seasonal pattern.

MannKind Corporation is a biopharmaceutical company focused on inhaled therapeutic products and devices for endocrine and orphan lung diseases, operating within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical industry. The company aims to improve patient outcomes through novel drug formulations and delivery technologies. Its major products and pipeline candidates include Afrezza, a rapid-acting inhaled insulin with a sBLA for pediatric use expected to be filed with a PDUFA date set for Q2 2026; Tyvaso DPI, developed with United Therapeutics, addresses pulmonary arterial hypertension; V-Go, a wearable insulin delivery device; MNKD-101, a pipeline candidate with Fast Track designation for nontuberculous mycobacterial lung disease, currently in a global Phase 3 trial; MNKD-201, a treatment for idiopathic pulmonary fibrosis, with plans to initiate a Phase 2 clinical trial by year-end 2025; FUROSCIX, acquired through scPharmaceuticals, aims to enhance MannKind's portfolio in cardiorenal medicine with a sNDA expected to receive a PDUFA date in Q3 2026; and MNKD-301 and MNKD-501, aimed at addressing cystic fibrosis and other conditions.

MannKind Corporation is headquartered in Danbury, Connecticut, and maintains a corporate office in Westlake Village, California. The company sells its products primarily within the United States through wholesale distributors and specialty pharmacies. Its manufacturing facilities are located in Danbury, Connecticut.

MannKind's brand reputation, measured by news mentions, appears lower compared to its industry peers, with no significant change in the last month, suggesting a relatively lower public profile or less active media engagement.

MannKind Corporation's ownership is a mix of institutional, retail, and individual investors. Institutional investors hold approximately 25.57% to 49.55% of the company's stock, with major holders including BlackRock, Inc., Vanguard Group Inc., and Rubric Capital Management LP. Insiders own approximately 2.70% to 2.84% of the company's shares, with CEO Michael Castagna owning 0.6%. Retail investors hold a significant portion, estimated at around 52% to 58.30% of the company.